Summary:
A phase IIB, randomized, double-blind, dose-ranging study to assess the efficacy and safety of MSTT1041A in patients with uncontrolled severe asthma.
Qualified Participants Must:
Be between 18 and 75 years of age at time of signing informed consent
Have a Body mass index (BMI) of 18-35kg/m₂ and weight > 40kg at screening
Have documented physician-diagnosed asthma for at least 12 months prior study visit
Patients on ICS + LABA(Inhaled Corticosteroid + Long-Acting Beta Agonists) such as Pulmicort, QVAR, Flovent, Asmanex, etc. + Advair, Symbicort, Dulera, etc.
Documented history of at least one asthma exacerbation within 12 months prior to screening while on daily ICS maintenance therapy
Hospitalization or emergency department or urgent care visit requiring administration of asthma treatment
If female of childbearing potential and committed to consistent and correct use of an acceptable method of birth control
Qualified Participants May Receive:
Can get compensated up to $1,900, free treatment and doctor consultations with 24hr emergency phone line;